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Abstract
Objective: The last decade has seen increasing evidence of dysfunctions 
in the endogenous cannabinoid system in schizophrenia and of its 
relationship with the typical cognitive impairment of the disorder. 
Studies in animal models, healthy volunteers, and psychotic patients 
clearly suggest an antipsychotic-like effect of cannabidiol. This study 
investigated the effects of cannabidiol on selective attention in 28 
schizophrenic patients using the Stroop Color Word Test and on these 
patients’ electrodermal responsiveness to auditive stimuli. Method: The 
subjects attended two experimental sessions, the first one without the 
administration of drugs. In the second session the subjects were divided 
into three groups that received either a single dose of cannabidiol 
300mg or cannabidiol 600mg or placebo. Results: The three groups 
did not differ significantly with respect to electrodermal measures in 
the two experimental sessions. When the first and second sessions were 
compared improved performance was found in all three groups, with 
patients who received placebo and cannabidiol 300mg performing better 
than those who received cannabidiol 600mg. Conclusion: The single, 
acute administration of cannabidiol seems to have no beneficial effects 
on the performance of schizophrenic patients in the Stroop Color Word 
Test, although the hypothesis that chronic administration may lead to 
improvement cannot be disregarded.
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Resumo
Objetivo: Descobertas relativas a possíveis disfunções do sistema canabinóide 
endógeno na esquizofrenia e sua relação com o prejuízo cognitivo característico 
da doença têm aumentado durante a última década. Estudos com modelos 
animais, voluntários saudáveis e pacientes psicóticos sugerem claramente que 
o canabidiol possui efeitos antipsicóticos. Este estudo investigou os efeitos do 
canabidiol sobre a atenção seletiva por meio do Stroop Color Word Test e 
a responsividade eletrodérmica a estímulos auditivos em 28 pacientes com 
esquizofrenia. Método: Duas sessões experimentais foram realizadas, a 
primeira sem a administração de drogas. Na segunda sessão, os sujeitos foram 
divididos em três grupos que receberam dose única de canabidiol 300mg, 
canabidiol 600mg ou placebo. Resultados: Os três grupos não diferiram 
significativamente no que se refere às medidas eletrodérmicas nas duas sessões 
experimentais. Os três grupos apresentaram melhora da primeira para a 
segunda avaliação, com os grupos placebo e canabidiol 300mg superiores ao 
grupo canabidiol 600mg. Conclusão: A administração aguda de canabidiol 
em dose única parece não ter efeitos benéficos sobre o desempenho de pacientes 
com esquizofrenia no Stroop Color Word Test, embora estes dados não 
sejam suficientes para refutar a hipótese de que a administração continuada 
de canabidiol possa resultar em melhora no funcionamento cognitivo em 
esquizofrenia.
Descritores: Esquizofrenia; Cognição; Canabidiol; Transtornos psicóticos
Introduction
In the middle of the 19th century, Moreau first employed 
marijuana as an experimental psychotomimetic substance.1 The 
discovery of cannabinoid receptors2 and endogenous ligands3 
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(anandamide – palmityl ethanolamide, 2-arachidonyl glycerol) 
supported the notion of a central neuromodulatory cannabinoid 
system, and there seems to exist a complete system with multiple 
cannabinoid receptors and anandamide-related compounds.4
There is evidence suggesting an association between Cannabis 
and psychosis or schizophrenia: the use of marijuana is more 
prevalent among patients with schizophrenia as compared to the 
healthy population;5 the extended use of marijuana can trigger 
psychotic episodes in schizophrenic patients;6 and increased 
anandamide levels have been found in the liquor of schizophrenic 
patients as compared with healthy controls.7 Additionally, 
cannabinoid agonists impair many cognitive functions (especially 
memory and attention) and similarities have been reported 
between the cognitive impairment seen in schizophrenia and 
that provoked by intoxication with Cannabis.8,9 Consistent 
with a potential contribution of the cannabinoid system to 
the physiopathology of schizophrenia, the highest densities of 
cannabinoid receptors are found in brain regions reported to be 
implicated in schizophrenia, including the PFC, basal ganglia, 
hippocampus, and anterior cingulate cortex.9 The association 
between cannabis and psychosis could be understood both as 
a hyperfunctioning of the endocannabinoid system and as an 
attempt to overcome a possible functional deficit of this system 
in patients with psychosis.
Scientific evidence gives support to attempts at testing 
cannabinoid antagonists as a possible therapeutic strategy for the 
treatment of psychiatric disorders.10
Since the 1970s, pioneering studies on CBD effects have been 
conducted in Brazil.11,12 Many of these studies have suggested 
that Cannabidiol (CBD), a cannabinoid devoid of the typical 
psychological effects of cannabis in humans,12 acts as an antagonist 
of the effects of D9-THC when administered simultaneously.12,13 
The study involving healthy volunteers suggested that CBD 
reduces both the anxiety and the psychotomimetic effects of 
D9-THC, leading to the proposition that this effect is due to an 
action of CBD itself.12 
The antipsychotic-like properties of CBD have been investigated 
in animal models using behavioral and neurochemical techniques 
which suggested that CBD has a pharmacological profile similar 
to that of atypical antipsychotic drugs.14 The results of two 
studies on healthy volunteers using perception of binocular depth 
inversion and ketamine-induced psychotic symptoms supported 
the proposal of the antipsychotic-like properties of CBD.15,16 
In addition, open case reports of schizophrenic patients treated 
with CBD17 and a preliminary report of a controlled clinical 
trial comparing CBD with an atypical antipsychotic drug18 have 
confirmed that this cannabinoid can be a safe and well-tolerated 
alternative treatment for schizophrenia. 
CBD increased c-Fos expression in many brain areas including 
the medial PFC and the cingulate gyrus,19 suggesting increased 
activity in these regions. Previous reports propose that these areas 
are involved in attentional processes, frequently impaired in 
schizophrenia.20 The cognitive impairments, mainly in attention, 
working memory, and aspects of executive function, are mostly 
associated with the long-term disability typically produced by 
the disorder, and the currently available treatments have limited 
efficacy against them.21,22 Since CBD increases the activity in areas 
related to attention, our hypothesis is that this cannabinoid could 
act by improving selective attention.
Selective attention can be assessed using the Stroop Color Word 
Test (SCWT)23 and is frequently associated with skin conductance 
responsiveness.24 A deficit in selective attention indicated by a 
higher number of errors in the SCWT is associated with low 
electrodermal responsiveness in schizophrenia patients.25
The objective of this study was to assess the performance of 
patients with schizophrenia in the SCWT under the influence 
of a single oral dose of CBD and verify whether this influence is 
associated with electrodermal responsiveness.
Method
1. Subjects
The sample consisted of 28 (18 male) outpatients with 
schizophrenia recruited at the university hospital of the Ribeirão 
Preto Medical School and from the city’s mental health outpatient 
clinic. Patients were more than 18 years of age and had at least 
four years of education, as well as a diagnosis of schizophrenia 
confirmed with the clinical interview26 for DSM-IV (SCID-CV) 
and score < 2 for each item of the Brief Psychiatric Rating Scale 
(BPRS)27 in order to avoid the inclusion of patients during an 
acute psychotic episode. Patients with any clinical conditions 
other than schizophrenia, under psychotropic medication 
different from the prescribed antipsychotic, pregnancy or 
suspected pregnancy, history of adverse reactions to marijuana, 
and previous history of substance abuse were not included 
in the study.
The patients and their accompanying relatives were informed 
about the procedures and provided written consent to participate. 
The study protocol was approved by the local ethics committee 
(process HCRP 805/97).
2. Psychiatric scales
The SCID-CV was used to confirm the diagnosis at the time of 
enrollment. The BPRS and the Positive and Negative Symptoms 
Scale (PANSS)28 were used to assess symptom profiles in the 
experimental sessions.
3. Stroop Color Word Test
A version with two cards, instead of the three originally 
proposed, was used in the application of the SCWT, according 
to the procedure proposed by Liddle & Morris.29 The first card 
(referred to as board I in the present study) contained 100 words 
(color names) printed in black, whereas the second card (board 
II) displayed 100 words describing color names and printed in 
colors different from their semantic meaning. The task consisted 
of reading the words on board I and naming the color of the ink 
of each word on board II. The time (seconds) taken to complete 
Hallak JEC et al.
58 • Revista Brasileira de Psiquiatria • vol 32 • nº 1 • mar2010
each board and the number of errors in reading and color naming 
were recorded, according to the method proposed elsewhere.30
4. Skin conductance level
Electrodermal measures were acquired through a computerized 
system for psychophysiological records (Contact Precision 
Instruments Inc., Boston – MA, USA) with constant voltage 
(0.6V), automatic back-off system, and Beckman skin electrodes 
connected to the subjects’ hand palm.
5. Drugs
CBD (kindly donated by Dr. R. Mechoulam from the University 
of Israel, Jerusalem), in doses of 300mg and 600mg, and placebo 
(starch) were prepared in identical gelatin capsules.
6. First experimental session
The participants were instructed to arrive at the laboratory at 8 
a.m. after having a standardized breakfast consisting of one glass 
of milk and a regular piece of bread. 
After evaluation with the BPRS and PANSS, participants were 
submitted to skin conductance level recordings in a room with 
sound and light attenuation. The subjects were asked to remove 
watches and jewelry and to wash their hands. They were then 
placed in a comfortable, reclined armchair and the electrodes were 
connected to the right hand palm of right-handed subjects and to 
the left palm in left-handed ones. The electrodes were attached by 
1cm-wide adhesive tape and the contact was ensured by filling the 
gap between the electrodes and the skin with conductive paste (KY 
gel, Johnson & Johnson). The following instructions were then 
given to the subjects: “Try to relax, stay seated and avoid moving 
your hand. You will hear some sounds at different intervals. 
Try to ignore them, keep your eyes open and do not sleep. The 
experiment will last approximately 15 minutes. Please wait until 
I come back to take the electrodes off.” The subjects put on their 
earphones and were observed from the control room through a 
unidirectional mirror.
After a 5-minute habituation period during which the 
volunteers remained silent, the stimulation period started, lasting 
for a subsequent 10 minutes. During this period, ten 80dB 
tones with one-second duration were presented in a frequency 
of 800Hz, at intervals ranging between 40 and 80 seconds in a 
pseudo-random order so that the volunteers could not predict 
the next stimulus. 
Skin conductance orienting responses (SCORs) were regarded as 
those with fluctuations equal to or higher than 0.05mS occurring 
within a responsiveness window of between one and five seconds 
after stimulus presentation. The non-responsiveness criteria 
adopted was the strict one: no electrodermal response (SCOR) 
of at least 0.05mS to any stimuli presented.31,32
After skin conductance levels were recorded, the participants 
sat by a table to perform the SCWT. The volunteers’ performance 
was recorded and independently evaluated afterwards by two 
skilled examiners.
7. Second experimental session
The participants were divided into three groups matched 
in terms of sex, years of education, age, and symptom profile 
(predominance of either negative or positive symptoms according 
to the scores of the BPRS and PANSS). The first and second 
groups would receive CBD 300mg and 600mg, respectively, and 
the third would be given placebo in a double-blind procedure. 
The second session took place with a minimum interval of 
one month after the first one. At the beginning of the session, 
the patients were again evaluated with the BPRS and PANSS in 
order to assess whether there had been any significant alteration in 
their psychopathological state. After this evaluation, the patients 
received one of the two CBD doses or placebo.
After a 60-minute period of free activities (drawing, reading, 
resting etc.), the participants were submitted to skin conductance 
level recordings and to the SCWT, in an identical procedure to 
that of the previous session.
8. Statistical analysis
Clinical and demographic characteristics of the three groups 
were compared by means of chi-square exact tests. BPRS and 
PANSS scores, time under antipsychotic treatment, and number of 
hospitalizations were compared by analysis of variance (ANOVA). 
The comparison between the three groups in relation to 
skin conductance level, spontaneous fluctuations, and number 
of SCOR was performed with the nonparametric test of 
Kruskal-Wallis.
The time (seconds) spent to complete each board and the 
number of errors in the SCWT in the first and second sessions was 
analyzed using a multifactor ANOVA to examine the main effects 
of group (placebo, CBD-300 and CBD-600), sex, electrodermal 
response (responsive and non-responsive), and duration of disease 
(< 5 years or > 5 years). Student’s t-test for related samples was 
used to perform intra-group comparisons between sessions. The 
level of statistical significance was set at p < 0.05.
 
Results
The analysis of the clinical, demographic, and electrodermal 
responsiveness data showed no differences among the three groups 
(Table 1), which suggests that they were homogeneous.
In the first session the ANOVA showed significant SCWT 
effect only for the electrodermal response factor (F
1,16 
= 5.98; p < 
0.05) related to time taken to complete board I. The mean time 
required for the responsive group was 77.8 (SEM = 11.7) and for 
the non-responsive it was was 119.7 (SEM = 12.3).
In the second assessment, the ANOVA showed a significant 
effect for group factors related to the number of errors on board 
II (F
2,16
 = 6.027; p = 0.014). The group that received CBD 600mg 
had a higher score compared to the other two. The number of 
errors on board II in sessions I and II is presented in Figure 1.
A decrease in the number of errors was observed for the three groups 
in the second session, although this reduction was smaller in the CBD 
600mg group and presented only a tendency to statistical significance. 
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Discussion
The three groups were comparable regarding the clinical 
and demographic characteristics as well as the electrodermal 
responsiveness and SCWT performances evaluated in the first 
session. The longer time taken to complete board I by the non-
responsive schizophrenia patients in the first session could be 
related to processing speed, since this function is engaged by board 
I of the Stroop test.24 This difference related to electrodermal 
responsiveness was not maintained in the second session, probably 
due to a learning effect.
The main finding of this study concerns the number of 
errors on board II of the SCWT. The participants’ performance 
improved from the first to the second session in terms of the errors 
committed. This difference was statistically significant for the 
placebo and CBD 300mg groups, although it was smaller and had 
a tendency to statistical significance in the CBD 600mg group.
The fact that the patients from all three groups improved in 
terms of the number of errors suggests a learning effect, with the 
possible development of strategies. These findings contrast with 
those by Chen et al.,33 who found stable performance in patients 
with schizophrenia over time, although a direct comparison cannot 
be made since those authors used a computer-based version of 
the SCWT and differences have been reported between the 
performance in the card and computer versions of the test.34 The 
results of the card version of the SCWT may stem from a series of 
factors (the need to sustain visual scanpath and to ignore a series 
of surrounding distracting effects, item by item and column by 
column choice, and selection of one stimulus in a series of stimuli) 
which allow for the development of strategies.35
The worse performance of the patients receiving CBD 600 
mg in relation to those receiving placebo or CBD 300mg could 
be due to the compound’s sedative effect, decreasing attention. 
Monti found that the acute administration of CBD has a short-
lasting hypnotic effect in rats.36 Pickens, in a study with mice, 
demonstrated CBD’s efficacy as a sedative agent in doses ranging 
between 1mg/kg and 20mg/kg.37 Hypnotic effects of CBD have 
also been reported21 in healthy volunteers (at 600, but not 300mg) 
and patients with insomnia.38
The results of this experiment do not support the hypothesis that 
CBD leads to cognitive improvement as assessed with the SCWT. 
This notion is based on the fact that CB1 agonists were shown 
to have a negative action on cognitive measures; for instance, 
in learning and working memory, both in man and animals.39 
According to these findings, some investigators suspected that 
a dysfunction in the cannabinoid system could be involved in 
the genesis of schizophrenia and in the disorder’s characteristic 
cognitive deterioration, which would enable the development of 
novel pharmacological approaches.
This action on cognitive function is probably largely due to the 
pattern of distribution of CB1 receptors in the brain, particularly in 
the substantia nigra, basal ganglia, cerebellum, and hippocampus.39 
The high concentration of cannabinoid receptors in the hippocampus 
strongly suggests that the cannabinoid system is involved in superior 
cognitive functioning.8 Thus, it could be expected that cannabinoid 
antagonist compounds would be able to improve cognitive 
performance. In spite of its low affinity for CB1 and CB2 receptors, 
experimental evidence has shown that CBD is capable of antagonizing 
CB1/CB2 receptor agonists at reasonably low concentrations.40 Thus 
an action could be expected from it in the sense of improving the 
performance of schizophrenic patients in the SCWT.
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This study has some limitations, including the relatively short 
time between the two sessions (one month), which could induce 
interference of learning, and the use of only one test of cognitive 
functioning.
The non-confirmation of the hypothesis posed above by 
using a single dose of CBD does not exclude the possibility 
that the chronic use may lead to the expected cognitive 
improvement, as happens with clozapine, which requires a 
period of adaptation to its sedative effect before its therapeutic 
action can be observed.
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